Literature DB >> 4056455

Inhibition of DNA synthesis of melanoma cells by azelaic acid.

H Leibl, G Stingl, H Pehamberger, H Korschan, K Konrad, K Wolff.   

Abstract

Azelaic acid was successfully used in the clinical treatment of 7 cases of lentigo maligna in that remission of the lesions was observed in all our patients. In order to elucidate mechanism(s) of the beneficial clinical effects, we studied the effect of azelaic acid on cultured melanoma cells. Cell numbers recovered from melanoma cell cultures grown for several days in the presence of 10 mM azelaic acid were 50-70% less than those recovered from control cultures or from cultures containing 10 mM adipic acid. This reduction of cell numbers was not due to a simple cytotoxic or cytolytic effect of azelaic acid but rather due to a dose-dependent inhibition of DNA synthesis. Interestingly, nontoxic concentrations of azelaic acid, which significantly reduced DNA synthesis of cultured melanoma cells, had no overt effect on the protein synthesis of these cells. It is conceivable that inhibition of DNA synthesis is one of the mechanisms by which azelaic acid prevents growth and proliferation of abnormal melanocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4056455     DOI: 10.1111/1523-1747.ep12277084

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  A possible mechanism of action for azelaic acid in the human epidermis.

Authors:  K U Schallreuter; J W Wood
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 2.  Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

3.  Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases.

Authors:  H Akamatsu; J Komura; Y Asada; Y Miyachi; Y Niwa
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.